Two months ago, when a federal appeals court rejected United Therapeutics’ attempt to revive an invalidated patent on its aging pulmonary arterial hypertension drug ...

As Sanofi continues to plot its planned separation from its consumer healthcare division, the business has reportedly attracted interest from multiple private equity...

The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for...

On AbbVie’s latest earnings call, analysts were curious whether long-time CEO Richard Gonzalez was weighing a succession plan now that Humira’s loss of U.S. exclusiv...

While the biopharma industry flocks to antibody-drug conjugates because of their ability to act as guided biological missiles to eliminate cancer cells, some co...

Over the last month, for those watching HBO’s macabre “True Detective: Night Country”—a TV series set in a harsh, sunless winter in a fictional Alaskan town—a contin...

Biogen’s business has been in decline thanks to fierce multiple sclerosis competition and a botched Alzheimer’s drug launch. To make matters worse, the U.S. Dep...

After trimming its headcount last year in an effort to cut down on operational expenses, VBI Vaccines found another way to improve its financial position with a...

Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer.  Verzenio failed to significantly prolong the t...

Even with Leqembi now sporting a full FDA approval and benefiting from the simpler Medicare coverage that distinction brings, Eisai and Biogen’s latest Alzheimer’s d...